
Finland · Medical devices startup
Marginum is a Finnish medical technology company founded in 2020 and based in Kuopio, Finland.
Funding reportedLast round: Seed
Follow Marginum and see its new rounds in your feed.Start following
Marginum is a Finnish medical technology company founded in 2020 and based in Kuopio, Finland.
The company specializes in fluorescence-guided oncological surgery through its innovative optical tissue monitoring systems. Marginum aims to enhance surgical performance and patient outcomes by enabling the safe identification of cancerous tissue during surgery, minimizing damage to healthy tissues. The flagship product, the CE-marked HIVEN® device, is a fluorescence-based tissue monitoring system that accurately detects fluorescent tumor tissues from surgical suction waste. This technology integrates smoothly into existing surgical workflows, supporting oncological procedures like tumor resection. Marginum is committed to advancing quantitative surgical techniques and is involved in ongoing usability assessments and clinical trials at prominent medical institutions, including the University of Illinois College of Medicine and University of Illinois Hospital & Clinics.
Funding, as reported
From Marginum's own website: 5 on the team.
AdvisersClinical Trial Physician
What they build
Known for
fluorescent biomarkershealth caredistributionmanufacturingminimally invasive detectionmultidisciplinary researchmedical equipment manufacturingfluorescence-guided surgerysurgical equipmenthospital & health carediagnostic imaginghealthtissue recognition technologymechanical or industrial engineeringservicesfluorescence-based tissue detection
Built with from their website
Google Tag ManagerFont AwesomeApacheCloudFlareViewport MetaTrustArcFacebook SDKCAPTCHAGoogle Font APIMicrosoft Exchange
Microsoft Azure HostingMicrosoft 365 Apps & ServicesMobile FriendlyBootstrapOpen GraphjQueryFancyBoxFacebook Social Plugins
Add your raise, your deck and your story, and put Marginum in front of investors. Or tell us what we have wrong.